Gina Mauro

Response predictive subtype–guided treatment identified patient cohorts with breast cancer that were more likely to achieve pCR with Dato-DXd plus durvalumab.

The addition of pembrolizumab to chemotherapy with or without radiation did not improve DFS across the intent-to-treat population of KEYNOTE-B21.

Ramucirumab plus trifluridine/tipiracil failed to improve overall survival vs TAS-102 alone in patients with heavily pretreated metastatic colorectal cancer.

The CheckMate 067 trial of patients with advanced melanoma is the longest follow-up of a checkpoint inhibitor in any tumor type.

Pembrolizumab continued to demonstrate improved survival vs ipilimumab in unresectable stage III or IV melanoma.

While adjuvant pembrolizumab and chemotherapy with or without radiation did not boost DFS in the overall high-risk endometrial cancer population, but showed a trend toward improved DFS in one patient subgroup.

Nivolumab, alone or with ipilimumab, significantly improved 10-year overall and melanoma-specific survival vs ipilimumab alone in advanced melanoma, according to final phase 3 CheckMate 067 trial data.

Lutetium Lu 177 dotatate shows consistent efficacy over high-dose octreotide in advanced GEP-NETs, according to data from the NETTER-2 trial.

AMG 193, an MTA-cooperative PRMT5 inhibitor, demonstrated responses and an acceptable safety profile across patients with MTAP-deleted solid tumors.

Patients with muscle-invasive bladder cancer who were treated with presurgical chemotherapy may have a 55% lower risk of death, research shows.